Brought to you by 
Genentech forms epigenetics research deal with Constellation; two of three targets terminated
31 Jul 2018
Executive Summary
In its first major epigenetics deal, Roche’s Genentech Inc. is forming a three-year research partnership with Constellation Pharmaceuticals Inc. (small molecules that modify chromatin to control gene expression) to develop drugs for cancer and other diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech forms epigenetics research deal with Constellation; two of three targets terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice